Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009. The prize awaiting biogeneric manufacturers such as Sandoz, Teva, and BioPartners is a global market worth $20 billion. Market

This report examines the key drivers and resistors behind the introduction of generic biologic medicines in the European Union, United States and the rest of the world.

With several blockbuster biological products approaching patent expiry, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. The generics industry is pus

This report focuses on the specific strategies adopted by companies involved in the biogenerics arena, asking:

• Why are specific strategies likely to be effective?
• Why are particular companies more likely to be successful in the r

The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European bio

With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the ma